Released Aug 5, 2021, after the close
10-Q filed Aug 6, 2021, 37 days after period end · 0001162194-21-000072
Q2 2021 · 10-Q
Revenue$31.02M$31.02M +19.0% vs Q2 2020−5.4% vs Q1 2021
Net Income-$17.14M-$17.14M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.23-$0.23 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$17,268,000N/M
Operating Cash Flowderived-$14,664,000N/M
Free Cash Flowderived-$18,836,000N/M
Margins · derived
Operating margin-55.7%−3.0 pt vs Q2 2020
Net margin-55.3%−5.3 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $31.02M | $26.06M | $28.20M | $26.43M |
| Net Income | -$17.14M | -$13.02M | -$13.75M | -$16.24M |
| EPS Diluted | -$0.23 | -$0.18 | -$0.20 | -$0.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR